CEO John Kilcoyne Reviews ReVision’s Success with the FDA & its Plans to Roll Out Raindrop
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 099″]
ReVision Optics built it – a corneal inlay capable of correcting presbyopia. The FDA approved it sooner than expected. Now the company needs to build it into a successful private-pay business.
John T. Kilcoyne
John T. Kilcoyne brings more than 29 years of experience in the medical device market to RVO. He has a demonstrated record in understanding the needs of both patients and physicians combined with an ability to move companies from development into the commercial market.